â– LECTURE OVERVIEW: Cori Disease (Glycogen Storage Disease Type III) is an autosomal recessive carbohydrate metabolism disorder characterized by the incomplete degradation of cellular glycogen.
â– PATHWAY ANALYSIS:
1. Debrancher Defect: Caused by a deficiency of the bifunctional Glycogen Debranching Enzyme (containing alpha-1,4 to alpha-1,4 glucan transferase and amylo-1,6-glucosidase activities).
2. Structural Structural Limits: Glycogen Phosphorylase can cleave alpha-1,4 glycosidic linkages until it reachers a limit dextrin (typically 4 glucose residues remaining on a branch).
3. Limit Dextrin Accumulation: Without debranching activity, glycogen degradation halts, leading to the accumulation of abnormal, highly branched glycogen molecules (limit dextrins) in the hepatic cytoplasm and skeletal muscle tissue.
4. Glucagon Response: Hypoglycemia is milder than in Von Gierke's (Type I) because gluconeogenesis remains 100% active and functional, allowing the liver to synthesize glucose de novo from lactate and amino acids.
â– MICROSCOPIC PATHOBIOLOGY:
Histopathologic biopsy reveals cellular atypia, pleomorphism, lipid vacuolar engorgement, or characteristic structural inclusions (e.g., specific nuclear changes, cytoplasmic inclusions) which are diagnostic for the pathology.
â– CLINICAL REGISTRY INSIGHTS:
Patient registry reviews depict high clinical validity in diverse populations, indicating highly correlated trends of symptom development and treatment responsiveness.
[HY-BOARD-1006]
🌟 Dynamic Clinical Key:
Cori disease presents with hepatomegaly, growth retardation, muscle weakness, and mild fasting hypoglycemia. It is differentiated from Von Gierke disease by the key presence of elevated creatine kinase (from muscle involvement), normal levels of lactic acid, and the histopathologic demonstration of limit dextrin aggregates. Confirm histologic findings with immunophenotypic cell markers using flow cytometry. Assess demographic representation when applying trial results to real-world patients.